Room temperature stable solid vaccine formulations suitable for needle free delivery

适合无针注射的室温稳定固体疫苗制剂

• 批准号: 131068
• 金额: $ 19.11万
• 依托单位: GLIDE PHARMACEUTICAL TECHNOLOGIES LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2013
• 资助国家: 英国
• 起止时间: 2013 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=131068
• 关键词: Room; temperature; stable; solid; vaccine

Needle free delivery of a room temperature stable vaccine which has the potential to reduce dosing frequency and / or to save antigen content has been a 'holy grail' of vaccine technology. Glide Pharma has developed a needle free device (recently completed a Phase 1 clinical study) that can deliver solid formulations and can uniquely meet all three requirements.Glide has previously demonstrated user acceptability and the dose sparing effect of the technology. The aim of this project is to evaluate room temperature stability which, theroretically, should be much easier to achieve with a solid vaccine compared to a liquid formulation.Glide can revolutionise vaccine delivery with its needle free, stable and low cost vaccine technology. This will enable developed countries to be better prepared for pandemic situations and to reduce healthcare costs, and the developing countries to enjoy the full benefits of modern vaccines.

室温稳定疫苗的无针递送，该疫苗有可能降低给药频率和 /或节省抗原含量的疫苗是疫苗技术的“圣杯”。 Glide Pharma已开发了无针器设备（最近完成了一项1期临床研究），该设备可以提供固体配方，并可以独特地满足所有三个要求。Glide先前已经证明了该技术的用户可接受性和剂量分配效果。该项目的目的是评估室温稳定性，与液体配方相比，在经过治疗上，使用固体疫苗应该更容易实现。Glide可以用无针，稳定和低成本的疫苗技术彻底改变疫苗的输送。这将使发达国家能够为大流行状况和降低医疗保健成本做好准备，以及发展中国家享受现代疫苗的全部收益。